Journal Article

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Desseigne, Françoise, Delbaldo, Catherine, Bécouarn, Yves, Ducreux, Michel, Chauffert, Bruno, Khemissa-Akouz, Faiza, Michel, Pierre, Bennouna, Jaafar, Gourgou-Bourgade, Sophie, Bouché, Olivier, Montoto-Grillot, Christine, Raoul, Jean-Luc, Ychou, Marc, Guimbaud, Rosine, Assenat, Eric, Conroy, Thierry, Adenis, Antoine, de la Fouchardière, Christelle, Bachet, Jean-Baptiste, Péré-Vergé, Denis

2011

Overview

In this study, a four-drug combination chemotherapy regimen was associated with objective responses in more than 30% of patients and increased survival by more than 4 months, as compared with standard gemcitabine. Pancreatic adenocarcinoma was the fourth leading cause of death from cancer in the United States in 2010, 1 and it carries a grim prognosis: the 5-year survival rate is 6% in Europe and the United States. 1 , 2 Gemcitabine became the reference regimen for advanced pancreatic cancer after a randomized trial showed significant improvement in the median overall survival as compared with fluorouracil administered as an intravenous bolus (5.6 vs. 4.4 months, P=0.002). 3 In the subsequent phase 3 trials of single-agent gemcitabine, 4 the median overall survival ranged from 5.0 to 7.2 months. The combination of gemcitabine with a variety of cytotoxic and . . .

• Publisher: Massachusetts Medical Society
• Subject: Adenocarcinoma - drug therapy / Adenocarcinoma - mortality / Adenocarcinoma - secondary / Adult / Aged / Antimetabolites, Antineoplastic - adverse effects / Antimetabolites, Antineoplastic - therapeutic use / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Biological and medical sciences / Camptothecin - administration & dosage / Camptothecin - analogs & derivatives / Clinical trials / Cytotoxicity / Deoxycytidine - adverse effects / Deoxycytidine - analogs & derivatives / Deoxycytidine - therapeutic use / Female / Fluorouracil - administration & dosage / Follow-Up Studies / Gastroenterology. Liver. Pancreas. Abdomen / General aspects / Humans / Leucovorin - administration & dosage / Liver. Biliary tract. Portal circulation. Exocrine pancreas / Male / Medical sciences / Middle Aged / Neoplasm Metastasis - drug therapy / Organoplatinum Compounds - administration & dosage / Pancreas / Pancreatic cancer / Pancreatic Neoplasms - drug therapy / Pancreatic Neoplasms - mortality / Pancreatic Neoplasms - pathology / Patients / Proportional Hazards Models / Quality of Life / Severity of Illness Index / Survival Analysis / Tumors